Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Colombes, France Clinical Trials

A listing of Colombes, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (1222) clinical trials

A Study of Eltrombopag in Patients With CMML and Thrombocytopenia

All eligible patients will be treated with eltrombopag for a minimum of twelve weeks and a maximum of 24 months.

Phase

1.76 miles

Learn More »

Therapeutic Hypothermia After Cardiac Arrest in Non Shockable Rhythm

Cardiac arrest is at present a major cause of mortality as well as a cause of disability for the surviving victims.In Europe, every year counts as 300,000 cardiac arrests responsible for 250,000 deaths. Thus, less than 20 % of patients discharged home with impaired quality of life associated with symptoms ...

Phase N/A

1.76 miles

Learn More »

Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .

Multicenter prospective phase II study evaluating regorafenib in older patients with metastatic colorectal cancer

Phase

1.76 miles

Learn More »

Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children

Scabies is a common condition, even in European countries, and the annual incidence seems to have increased over the past several years. Children and infants represent one-third of patients with scabies. Diagnostic features comprise pruritus, skin burrows and the delta jet wing dermoscopic sign. In many countries, topical permethrin is ...

Phase

1.76 miles

Learn More »

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis

The study duration per patient is expected to be approximately 32 weeks, with up to 4-week screening, 24 weeks treatment, and 2-4 weeks post-treatment observations.

Phase

1.76 miles

Learn More »

Economic and Social Disparities and Breast Cancer

All patients seeking treatment for breast cancer, regardless of the stage, can be included in the study. Three scores of precariousness will be applied to all patients (EPICES score, Pascal score and the European Deprivation Index). Patients identified as precarious by at least one of those three scales will be ...

Phase N/A

1.76 miles

Learn More »

Bronchoalveolar Lavages for Cytologic Assessment in Intensive Care Unit Patients

Secondary objectives will be to assess the frequency of poor quality bronchoalveolar lavages (as defined by either more than 5% bronchial epithelial cell count to less than 50,000 alveolar cells per mL) assess the contribution of a given bronchoalveolar lavage to the diagnostic work up assess the contribution of a ...

Phase N/A

1.76 miles

Learn More »

Ponatinib for FLT3-ITD Acute Myelogenous Leukemia

This project is part of a joint ALFA and GOELAM strategy aiming to improve the survival of patients with newly diagnosed Acute Myeloid Leukemia (AML) aged 18-70 years. The basis of this strategy is to evaluate intensified conventional chemotherapy and targeted drugs in selected disease-risk subgroups of adult patients with ...

Phase

1.76 miles

Learn More »

Study to Improve OS in 18 to 60 Year-old Patients Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient strategies. Within the intermediate risk AML group, optimal GvHD prophylaxis following ...

Phase

1.76 miles

Learn More »

Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4

Purpose : The main objective of this study is to assess the efficacy and tolerance of the addition of repeated doses of low doses (3mg/m2) of Gemtuzumab Ozogamicin (GO) in addition with standard doses of Ara-C in previously untreated patients aged 60 to 80 years with de novo acute myeloblastic ...

Phase

1.76 miles

Learn More »